Urology Annals

CASE REPORT
Year
: 2017  |  Volume : 9  |  Issue : 1  |  Page : 86--88

Prostatic intraepithelial neoplasia-like ductal prostatic adenocarcinoma: A case suitable for active surveillance?


Soroush Rais-Bahrami1, Melissa R Dillard2, Grace G Zhu3, Jennifer B Gordetsky4,  
1 Department of Urology and Radiology, University of Alabama at Birmingham, Birmingham, AL, USA
2 Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
3 Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA
4 Department of Urology and Pathology, University of Alabama at Birmingham, Birmingham, AL, USA

Correspondence Address:
Soroush Rais-Bahrami
Department of Urology, University of Alabama at Birmingham, Faculty Office Tower 1107, 510 20th Street South, Birmingham, AL 35294
USA

Abstract

In contrast to typical prostatic ductal adenocarcinoma, prostatic intraepithelial neoplasia (PIN)-like ductal adenocarcinoma is a rare variant of prostate cancer with low-grade clinical behavior. We report a case of a 66-year-old African-American male with an elevated serum prostate-specific antigen who underwent multiparametric prostate magnetic resonance imaging (MRI) and MRI/ultrasound fusion-guided biopsies. Pathology demonstrated low-volume Gleason score 3 + 3 = 6 (Grade Group 1), acinar adenocarcinoma involving one core and PIN-like ductal adenocarcinoma on a separate core. Herein, we discuss the potential role of active surveillance for patients with this rare variant of prostate cancer found in the era of advanced imaging with multiparametric MRI for prostate cancer.



How to cite this article:
Rais-Bahrami S, Dillard MR, Zhu GG, Gordetsky JB. Prostatic intraepithelial neoplasia-like ductal prostatic adenocarcinoma: A case suitable for active surveillance?.Urol Ann 2017;9:86-88


How to cite this URL:
Rais-Bahrami S, Dillard MR, Zhu GG, Gordetsky JB. Prostatic intraepithelial neoplasia-like ductal prostatic adenocarcinoma: A case suitable for active surveillance?. Urol Ann [serial online] 2017 [cited 2019 Dec 14 ];9:86-88
Available from: http://www.urologyannals.com/text.asp?2017/9/1/86/198829


Full Text

 Introduction



Prostate cancer is the most common noncutaneous malignancy diagnosed in American men.[1] Advances in multiparametric magnetic resonance imaging (MP-MRI), incorporating both anatomic and functional imaging sequences, allow for identification of concerning lesions within the prostate gland suspicious for harboring prostate cancer. When targeted for biopsy, suspicious lesions delineated by MP-MRI have been shown to improve detection of prostate cancer, especially higher grade disease areas.[2],[3] Adoption of MP-MRI and MRI-ultrasound (US) fusion-guided biopsy has been demonstrated to play a potentially integral role in active surveillance (AS) for appropriately chosen patients with low-risk, clinically indolent prostate cancers.[4],[5] Specifically, targeted biopsies of MRI-detected lesions within the prostate have increased confidence in safely selecting patients appropriate for AS due to the improved risk stratification. Herein, we present a case of MRI/US fusion-guided biopsy with pathology demonstrating low-volume Gleason score 3 + 3 = 6 (Grade Group 1), prostatic adenocarcinoma involving one core and a separate core with prostatic intraepithelial neoplasia (PIN)-like ductal adenocarcinoma. To date, the report of MRI-targeted biopsy and PIN-like ductal adenocarcinoma of the prostate has not been reported in the context of potentially selecting AS as a method of clinical management.

 Case Report



A 66-year-old African-American male presented for a prostate biopsy prompted by an elevated screening serum prostate-specific antigen (PSA) level. Before biopsy, he underwent MP-MRI, which demonstrated two intraprostatic lesions suspicious for harboring prostate cancer suitable for targeted biopsy. Both lesions were classified as low-suspicion for harboring clinically significant prostate cancer. Following the diagnostic MP-MRI, the patient underwent targeted biopsies through MRI/US fusion-guidance using the UroNav software fusion platform (InVivo, Philips, Gainesville, FL, USA) in addition to standard 12-core extended sextant biopsy. On fusion biopsy, pathology showed low-volume Gleason score 3 + 3 = 6 (Grade Group 1), acinar adenocarcinoma involving one core as well as PIN-like ductal adenocarcinoma involving a separate core. We questioned whether this patient could be considered a safe candidate for AS given the presence of PIN-like ductal adenocarcinoma.

 Discussion



Ductal adenocarcinomas comprise 0.4%–0.8% of all diagnosed prostate cancers and are characterized by atypical tall columnar cells arranged in a variety of patterns (cribriform, papillary, single cell, solid, or PIN-like).[6],[7] PIN-like ductal adenocarcinoma can be distinguished from high-grade PIN based on morphologic features more characteristic of ductal adenocarcinoma and by the absence of basal cells in the atypical glands [Figure 1], [Figure 2], [Figure 3].[7],[8] It is important to recognize PIN-like ductal adenocarcinoma as a separate entity from other variants of ductal adenocarcinoma due to its clinical behavior. Although ductal adenocarcinomas are generally comparable to Gleason score 4 + 4 = 8 (Grade Group 4) prostatic carcinoma, the PIN-like pattern of ductal adenocarcinoma often behaves similar to Gleason score 3 + 3 = 6 (Grade Group 1), acinar prostatic carcinoma offering a much more favorable prognosis.[8] In a clinicopathologic study of 28 cases of PIN-like ductal adenocarcinoma, only one of the PIN-like ductal adenocarcinomas at the time of radical prostatectomy was associated with extraprostatic extension, which was noted focally.[8] Patients with this variant, hence, may potentially be safely selected candidates for AS.{Figure 1}{Figure 2}{Figure 3}

MP-MRI and MRI/US fusion-guided prostate biopsies have shown optimized detection of clinically significant prostate cancers in large series compared to the standard 12-core extended sextant biopsy.[3] Prostate imaging with MRI and targeted biopsy has also been utilized to confirm safe AS candidacy, allowing for detection of otherwise occult cancer foci or areas of higher grade or higher volume disease.[4],[9] Furthermore, serial MRI for continued AS has been reported by several centers who have been early adopters and developers of the MRI fusion biopsy techniques.[5],[10]

To date, reports of prostatic ductal adenocarcinoma and imaging features seen on MP-MRI have been reported, but never in the setting of MRI/US fusion-guided biopsy with detection of the rare variant of PIN-like ductal adenocarcinoma.[11] With the confidence that MRI and targeted biopsy did not find any intermediate or high-grade acinar adenocarcinoma, we questioned whether this patient would be considered a safe candidate for AS given the caveat of the small focus in a single biopsy core of PIN-like ductal adenocarcinoma. Given the nonaggressive clinical behavior of PIN-like ductal adenocarcinoma, we proposed that AS would be a safe option in this case. The patient elected to pursue AS, which entailed serial clinical examinations, serum PSA assessment, MP-MRI evaluating for dynamic change, and follow-up biopsy to ensure timely assessment of grade or stage increase to allow for early definitive treatment with curative intent. As with other patients pursuing AS at our institution, we find great value in the use of MP-MRI for serial imaging and targeted biopsy to confirm safe AS eligibility.

Further investigation with larger patient series and longer follow-up, potentially in the setting of multi-institutional efforts due to the rarity of this diagnosis, is necessary to determine the safe eligibility for AS for patients with this histopathologic finding.

PIN-like ductal adenocarcinoma behaves similar to Gleason score 3 + 3 = 6 (Grade Group 1), prostatic carcinoma. In the setting of MRI/US fusion-guided biopsy with Gleason score 3 + 3 = 6 (Grade Group 1), acinar prostatic carcinoma involving one core and a separate focus of PIN-like ductal adenocarcinoma found on another core, AS is considered a safe management option. Close clinical follow-up, integrating serial biomarker evaluation, imaging, and biopsy are recommended in this case.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, et al. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 2013;190:1721-7.
3Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015;313:390-7.
4Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 2013;119:3359-66.
5Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, et al. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol 2015;33:202.e1-7.
6Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 1985;9:595-609.
7Epstein JI. Prostatic ductal adenocarcinoma: A mini review. Med Princ Pract 2010;19:82-5.
8Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: A clinicopathologic study of 28 cases. Am J Surg Pathol 2008;32:1060-7.
9Okoro C, George AK, Siddiqui MM, Rais-Bahrami S, Walton-Diaz A, Shakir NA, et al. Magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy significantly outperforms systematic 12-core biopsy for prediction of total magnetic resonance imaging tumor volume in active surveillance patients. J Endourol 2015;29:1115-21.
10Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, et al. Serial magnetic resonance imaging in active surveillance of prostate cancer: Incremental value. J Urol 2016;195:1421-7.
11Coffey N, Schieda N, Cron G, Gulavita P, Mai KT, Flood TA. Multi-parametric (mp) MRI of prostatic ductal adenocarcinoma. J Magn Reson Imaging 2015;41:1639-45.